How The Feds Discourage Prescription Drug Competition
By Scott Gottlieb (original source Forbes)
“There’s a growing refrain among those who pay for healthcare services that they want new products to deliver more value. When it comes to prescription drugs, this is usually interpreted to mean medicines that provide more benefit, at lower costs per increment of clinical advantage. Drugs that deliver more bang for the buck.
But pharmaceutical competition usually turns on claims of absolute efficacy rather than the relative and comparative merits of a medicine. There is one obvious reason.
Drug companies can rarely make claims around the value of their medicines.”
Click here to read more